Table 1 Clinical characteristics of patients

Age

0.269

Median (IQR)

49 (45–58)

46 (39–51)

51 (45–60)

 < 50 years

37 (50.7%)

11 (64.7%)

26 (46.4%)

 ≥ 50 years

36 (49.3%)

6 (35.3%)

30 (53.6%)

Subtype

0.098

 HR + /HER2 + 

15 (20.5%)

5 (29.4%)

10 (17.9%)

 HR + /HER2-

34 (46.6%)

4 (23.5%)

30 (53.6%)

 HR- /HER2 + 

6 (8.2%)

1 (5.9%)

5 (8.9%)

 TNBC

18 (24.7%)

7 (41.2%)

11 (19.6%)

Clinical stage

0.007**

 II

49 (67.1%)

16 (94.1%)

33 (58.9%)

 III

24 (32.9%)

1 (5.9%)

23 (41.1%)

Primary tumor (T)

0.935

 T1

9 (12.3%)

2 (11.8%)

7 (12.5%)

 T2

47 (64.4%)

12 (70.6%)

35 (62.5%)

 T3

16 (21.9%)

3 (17.6%)

13 (23.2%)

 T4

1 (1.4%)

0 (0.0%)

1 (1.8%)

Regional lymph nodes (N)

0.004**

 N0

14 (19.2%)

8 (47.1%)

6 (10.7%)

 N1

43 (58.9%)

9 (52.9%)

34 (60.7%)

 N2

11 (15.1%)

0 (0.0%)

11 (19.6%)

 N3

5 (6.8%)

0 (0.0%)

5 (8.9%)

Distant metastases (M)

~ 

 M0

73 (100.0%)

17 (100.0%)

56 (100.0%)

NAC regimen

0.287

 EC-T

49 (67.1%)

10 (58.8%)

39 (69.6%)

 EC-TH

13 (17.8%)

3 (17.6%)

10 (17.9%)

 TEC

5 (6.8%)

3 (17.6%)

2 (3.6%)

 AC-TH

3 (4.1%)

1 (5.9%)

2 (3.6%)

 EC-TCb

3 (4.1%)

0 (0.0%)

3 (5.4%)

ADT regimen

0.141

 No systemic ADT

18 (24.7%)

7 (41.2%)

11 (19.6%)

 Hormone therapy

34 (46.6%)

4 (23.5%)

30 (53.6%)

 Targeted therapy

6 (8.2%)

1 (5.9%)

5 (8.9%)

 Hormone + targeted

15 (20.5%)

5 (29.4%)

10 (17.9%)

Radiotherapy

0.012*

 Yes

38 (52.1%)

4 (23.5%)

34 (60.7%)

 No

35 (47.9%)

13 (76.5%)

22 (39.3%)